## CLAIMS

What is claimed is:

- A recombinant <u>Helicobacter pylori</u> protein, or
   a derivative or fragment thereof.
  - 2. The recombinant protein according to claim 1 wherein the protein is a <u>Helicobacter pylori</u> cytotoxin or a precursor, derivative or fragment thereof.

10

3. The recombinant protein according to claim 2 wherein the cytotoxin, precursor, derivative or fragment thereof has the amino acid sequence of Figure 2, or a portion thereof.

15

4. The recombinant protein according to claim 1 wherein the protein is a <u>Helicobacter pylori</u> cytotoxin associated immunodominant antigen, or a derivative or fragment thereof.

20

5. The recombinant protein according to claim 4 wherein the cytotoxin associated immunodominant antigen, derivative or fragment has the amino acid sequence of Figure 4, or a portion thereof.

- 6. The recombinant protein according to claim 1 wherein the protein is a <u>Helicobacter pylori</u> heat shock protein, or a derivative or fragment thereof.
- 7. The recombinant protein according to claim 6, wherein the heat shock protein, derivative or fragment has the amino acid sequence of Figure 5 or a portion thereof.
- 8. The recombinant protein according to claim 2 or 3 wherein the recombinant protein exhibits substantially no toxicity, or substantially reduced toxicity.
  - 9. The recombinant protein according to any one of claims 4 to 7 wherein the recombinant protein is

immunogenic and exhibits no functional contribution to toxicity, or a substantially reduced functional contribution to toxicity.

- 5 10. The recombinant protein according to claim 8 or 9 wherein the recombinant protein is chemically modified to reduce or abolish toxicity or functional contribution to toxicity.
- 10. The recombinant protein according to claim 8 or 9 wherein the recombinant protein contains one or more amino acid substitutions or deletions.
- 12. The recombinant protein according to any one of the preceding claims which is labelled or coupled to a solid support.
- 13. The recombinant protein according to any one of claims 1 to 11 for use in the treatment of <a href="Helicobacter">Helicobacter</a>
  20 <a href="pylori">pylori</a> infection.
  - 14. The recombinant protein according to any one of claims 1 to 11 for use as a vaccine.
- 25 15. A vaccine or therapeutic composition comprising a recombinant protein according to any one of claims 1 to 11 and a pharmaceutically acceptable carrier.
- 30

  16. The vaccine or therapeutic composition according to claim 15 comprising two or more recombinant proteins according to any one claims 1 to 11.
- 17. The vaccine or therapeutic composition 35 according to claim 16 comprising, in combination, two or more of
  - i) a recombinant <u>Helicobacter pylori</u> cytotoxic protein precursor, derivative or fragment thereof,
    - ii) a <u>Helicobacter pylori</u> recombinant cytotoxin

associated immunodominant antigen, or a derivative or fragment thereof,

- iii) <u>Helicobacter pylori</u> recombinant heat shock protein or a derivative or fragment thereof and/or
  - iv) a <u>Helicobacter pylori</u> urease.
- 18. The vaccine or therapeutic composition according to any one of claims 15 to 17 comprising an adjuvant.

10

15

20

25

30

35

- 19. A method for the preparation of a vaccine or therapeutic composition according to any one of claims 15 or 18 comprising bringing one or more recombinant proteins according to any one of claims 1 to 11 into association with a pharmaceutically acceptable carrier and optionally an adjuvant.
- 20. An immunodiagnostic assay comprising at least one step involving as at least one binding partner, a recombinant protein according to any one of claims 1 to 12, optionally labelled or coupled to a solid support.
- 21. An immunodiagnosis kit for performing an assay according to claim 20, comprising at least one recombinant protein according to any one of claims 1 to 20.
  - 22. Use of one or more recombinant proteins according to any one of claims 1 to 11 for the manufacture of a medicament for the treatment of <u>Helicobacter pylori</u> infection.
  - 23. A method of treatment of an individual infected with <u>Helicobacter pylori</u> comprising administering an effective amount of a recombinant protein according to 1 to 11.
  - 24. The method of treatment according to claim 23 comprising administering an effective amount of, in combination, two or more of

- i) a recombinant <u>Helicobacter pylori</u> cytotoxic protein precursor, derivative or fragment thereof,
- ii) a <u>Helicobacter pylori</u> recombinant cytotoxin associated immunodominant antigen, or a derivative or fragment thereof,
- iii) a <u>Helicobacter pylori</u> recombinant heat shock protein or a derivative or fragment thereof and/or
  - iv) a <u>Helicobacter pylori</u> urease.

5

15

20

25

30

- 25. A method of vaccination comprising administering an immunologically effective amount of, in combination, two or more of
  - i) a recombinant <u>Helicobacter pylori</u> cytotoxic protein precursor, derivative or fragment thereof,
  - ii) a <u>Helicobacter pylori</u> recombinant cytotoxin associated immunodominant antigen, or a derivative or fragment thereof,
    - iii) a <u>Helicobacter pylori</u> recombinant heat shock protein or a derivative or fragment thereof and/or
      - iv) a Helicobacter pylori urease.
      - 26. A recombinant polynucleotide encoding a recombinant protein according to any one of claims 1 to 11.
    - 27. A recombinant polynucleotide encoding a <u>Helicobacter pylori</u> cytotoxic protein or a derivative or fragment thereof comprising all or part of the nucleotide sequence of Figure 1.
    - 28. A recombinant polynucleotide encoding a Helicobacter pylori recombinant cytotoxin associated immunodominant antigen or a derivative or fragment thereof comprising all or a part of the nucleotide sequence of Figure 4.
    - 29. A recombinant polynucleotide encoding a Helicobacter pylori recombinant heat shock protein or a derivative or fragment thereof comprising all or a part of

the nucleotide sequence of Figure 5.

- 30. A polynucleotide probe comprising all or part of the recombinant polynucleotide according to any one of claims 26 to 29.
- 31. A nucleic acid assay wherein in at least one step involves a polynucleotide probe according to claim 30.
- 32. A kit for performing a nucleic acid assay comprising at least one polynucleotide probe according to claim 30.
- 33. A polynucleotide amplification process employing a polynucleotide primer wherein in at least one primer is a recombinant polynucleotide comprising all or part of the recombinant polynucleotide according to any one of claims 26 to 29.
- 34. A kit for performing a polynucleotide amplification process employing a polynucleotide primer wherein in at least one primer is a recombinant polynucleotide comprising all or part of the recombinant polynucleotide according to any one of claims 26 to 29.

- 35. A vector comprising a recombinant polynucleotide according to any one of claims 26 to 29.
- 36: A host cell transformed with a vector according to claim 35.
- 37. A method for the production of a recombinant polypeptide according to any one of claims 1 to 11, comprising culturing a host cell according to claim 36 and isolating the recombinant polypeptide.